UBE2L1: A Protein Target for Neurodegenerative Disorders and Other Diseases

Target Name: UBE2L1

NCBI ID: G283556

UBE2L1

UBE2L1: A Protein Target for Neurodegenerative Disorders and Other Diseases

UBE2L1 (UBE2L7P), a protein located in the endoplasmic reticulum (ER), has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its unique structure and localization to the ER make it an attractive target for small molecules, antibodies, and other therapeutic agents.

UBE2L1 is a 21-kDa protein that consists of a 194 amino acid residue. It is localized to the ER, where it plays a critical role in the regulation of protein synthesis and degradation. The ER is a specialized organelle that plays a crucial role in the folding and processing of proteins, and UBE2L1 is involved in several essential functions, including protein quality control, degradation, and modulation.

One of the key functions of UBE2L1 is its role in the degradation of misfolded proteins. During the translation of mRNAs, proteins often misfold into byproducts that do not self-associate, called "hybrids." These hybrids often cannot effectively participate in cellular metabolism and biological processes and may cause harm to cells. UBE2L1 maintains the stability and solubility of intracellular proteins by binding and degrading these hybrids, thus ensuring the smooth progress of cell metabolism.

In addition, UBE2L1 is also involved in the regulation of cell cycle and the regulation of cell growth and apoptosis. During the cell cycle, UBE2L1 binds to tubulin and affects the assembly and depolymerization of microtubules. This role allows UBE2L1 to play a key role in cell cycle regulation.

During tumor occurrence and development, the expression level of UBE2L1 changes. Studies have found that the expression level of UBE2L1 is positively correlated with various tumor types, such as lung cancer, liver cancer, breast cancer, etc. Moreover, the expression level of UBE2L1 is also related to the invasion and metastasis ability of tumors. Therefore, UBE2L1 is regarded as a potential tumor target.

In addition, the relationship between UBE2L1 and neurodegenerative diseases has also attracted attention. As we age, nerve cell degeneration leads to neuronal death and loss of neuronal connections. And UBE2L1 plays a key role in this process. Studies have shown that loss of UBE2L1 leads to neuronal death and synaptic loss, thereby exacerbating neurodegenerative diseases.

In neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, etc., drug intervention of UBE2L1 has made certain progress. For example, researchers have found that inhibitors of UBE2L1 can significantly improve motor function and cognitive abilities in patients with neurodegenerative diseases. In addition, some studies have also shown that UBE2L1 intervention can regulate the oxidative stress state of neurons, thereby alleviating the effects of neurodegenerative diseases.

In addition to neurodegenerative diseases, UBE2L1 may also play important roles in other disease areas. For example, the upregulation of UBE2L1 expression in liver diseases has attracted widespread attention. Studies have shown that the liver expression level of UBE2L1 is closely related to liver disease risk and liver function. Therefore, UBE2L1 may become a potential therapeutic target for liver diseases.

In addition, the role of UBE2L1 in the immune system also deserves attention. Studies have shown that the expression of UBE2L1 is up-regulated in immune cells, which may be closely related to processes such as activation, proliferation and sorting of immune cells. Therefore, UBE2L1 may be a potential immunotherapy target.

As a new target, UBE2L1 has attracted widespread research interest. In the future, researchers will continue to explore the role of UBE2L1 in disease and explore its clinical application value. At the same time, researchers will also conduct in-depth studies on the structure and function of UBE2L1 to provide a theoretical basis for the development of new drugs.

Protein Name: Ubiquitin Conjugating Enzyme E2 L1 (pseudogene)

The "UBE2L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets